Quantitative Systematic Strategies LLC acquired a new stake in Allscripts Healthcare Solutions Inc (NASDAQ:MDRX) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 29,154 shares of the software maker’s stock, valued at approximately $350,000.

Several other large investors also recently modified their holdings of the company. Fisher Asset Management LLC lifted its position in Allscripts Healthcare Solutions by 117.6% during the first quarter. Fisher Asset Management LLC now owns 5,192,457 shares of the software maker’s stock worth $64,127,000 after buying an additional 2,806,220 shares during the period. Silvercrest Asset Management Group LLC lifted its position in Allscripts Healthcare Solutions by 26.5% during the first quarter. Silvercrest Asset Management Group LLC now owns 4,438,241 shares of the software maker’s stock worth $54,812,000 after buying an additional 929,720 shares during the period. Dalton Greiner Hartman Maher & Co. lifted its position in Allscripts Healthcare Solutions by 39.2% during the second quarter. Dalton Greiner Hartman Maher & Co. now owns 3,174,511 shares of the software maker’s stock worth $38,094,000 after buying an additional 893,405 shares during the period. Fort Washington Investment Advisors Inc. OH lifted its position in Allscripts Healthcare Solutions by 72.9% during the first quarter. Fort Washington Investment Advisors Inc. OH now owns 1,874,300 shares of the software maker’s stock worth $23,148,000 after buying an additional 790,000 shares during the period. Finally, UBS Group AG lifted its position in Allscripts Healthcare Solutions by 734.9% during the first quarter. UBS Group AG now owns 894,859 shares of the software maker’s stock worth $11,051,000 after buying an additional 787,681 shares during the period.

Several research firms recently weighed in on MDRX. ValuEngine upgraded Allscripts Healthcare Solutions from a “sell” rating to a “hold” rating in a research report on Thursday, August 2nd. BidaskClub downgraded Allscripts Healthcare Solutions from a “hold” rating to a “sell” rating in a research report on Wednesday, June 13th. Maxim Group reiterated a “buy” rating and set a $18.00 target price on shares of Allscripts Healthcare Solutions in a research report on Friday, May 4th. SunTrust Banks upgraded Allscripts Healthcare Solutions from a “hold” rating to a “buy” rating and increased their target price for the stock from $10.78 to $16.13 in a research report on Friday, May 4th. They noted that the move was a valuation call. Finally, Cantor Fitzgerald reiterated a “buy” rating and set a $18.00 target price on shares of Allscripts Healthcare Solutions in a research report on Thursday, May 3rd. Four research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $16.37.

Allscripts Healthcare Solutions stock opened at $14.81 on Friday. The stock has a market capitalization of $2.61 billion, a PE ratio of 29.86, a PEG ratio of 1.97 and a beta of 1.09. The company has a current ratio of 0.94, a quick ratio of 0.94 and a debt-to-equity ratio of 1.41. Allscripts Healthcare Solutions Inc has a 12 month low of $10.78 and a 12 month high of $16.13.

Allscripts Healthcare Solutions (NASDAQ:MDRX) last released its quarterly earnings data on Thursday, August 2nd. The software maker reported $0.18 EPS for the quarter, hitting analysts’ consensus estimates of $0.18. The company had revenue of $525.50 million for the quarter, compared to the consensus estimate of $536.93 million. Allscripts Healthcare Solutions had a return on equity of 8.26% and a net margin of 0.10%. The company’s quarterly revenue was up 23.3% compared to the same quarter last year. During the same period last year, the business posted $0.15 EPS. equities analysts forecast that Allscripts Healthcare Solutions Inc will post 0.56 earnings per share for the current fiscal year.

Allscripts Healthcare Solutions declared that its board has approved a share repurchase program on Thursday, August 2nd that permits the company to repurchase $250.00 million in outstanding shares. This repurchase authorization permits the software maker to repurchase up to 11.3% of its stock through open market purchases. Stock repurchase programs are generally an indication that the company’s board of directors believes its stock is undervalued.

In other news, CFO Dennis Olis sold 25,000 shares of the firm’s stock in a transaction dated Thursday, August 16th. The stock was sold at an average price of $14.50, for a total value of $362,500.00. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, President Richard J. Poulton sold 15,000 shares of the firm’s stock in a transaction dated Friday, June 15th. The stock was sold at an average price of $12.40, for a total value of $186,000.00. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 45,000 shares of company stock worth $609,650. Company insiders own 0.75% of the company’s stock.

About Allscripts Healthcare Solutions

Allscripts Healthcare Solutions, Inc provides information technology solutions and services to healthcare organizations in the United States, Canada, and internationally. It offers electronic health records, connectivity, private cloud hosting, outsourcing, analytics, patient engagement, clinical decision support, and population health management solutions.

Featured Article: What is the NASDAQ?

Want to see what other hedge funds are holding MDRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allscripts Healthcare Solutions Inc (NASDAQ:MDRX).

Institutional Ownership by Quarter for Allscripts Healthcare Solutions (NASDAQ:MDRX)

Receive News & Ratings for Allscripts Healthcare Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allscripts Healthcare Solutions and related companies with MarketBeat.com's FREE daily email newsletter.